Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment

Abstract. The goal of our study was to determine the susceptibility of different pancreatic cell lines to clinically applicable photodynamic therapy (PDT). The efficacy of PDT of two different commercially available photosensitizers, verteporfin and sodium porfimer, was compared using a panel of four different pancreatic cancer cell lines, PANC-1, BxPC-3, CAPAN-2, and MIA PaCa-2, and an immortalized non-neoplastic pancreatic ductal epithelium cell line, HPNE. The minimum effective concentrations and dose-dependent curves of verteporfin and sodium porfimer on PANC-1 were determined. Since pancreatic cancer is known to have significant stromal components, the effect of PDT on stromal cells was also assessed. To mimic tumor–stroma interaction, a co-culture of primary human fibroblasts or human pancreatic stellate cell (HPSCs) line with PANC-1 was used to test verteporfin-PDT-mediated cell death of PANC-1. Two cytokines (TNF-α and IL-1β) were used for stimulation of primary fibroblasts (derived from human esophageal biopsies) or HPSCs. The increased expression of smooth muscle actin (α-SMA) confirmed the activation of fibroblasts or HPSC upon treatment with TNF-α and IL-1β. Cell death assays showed that both sodium porfimer- and verteporfin-mediated PDT-induced cell death in a dose-dependent manner. However, verteporfin-PDT treatment had a greater efficiency with 60  ×   lower concentration than sodium porfimer-PDT in the PANC-1 incubated with stimulated fibroblasts or HPSC. Moreover, activation of stromal cells did not affect the treatment of the pancreatic cancer cell lines, suggesting that the effects of PDT are independent of the inflammatory microenvironment found in this two-dimensional culture model of cancers.

[1]  T. Delaney,et al.  Photodynamic therapy of cancer. , 1988, Comprehensive therapy.

[2]  Paul M. Ripley,et al.  Photodynamic therapy for cancer of the pancreas , 2002, Gut.

[3]  F. Real,et al.  A genetic roadmap of pancreatic cancer: still evolving , 2017, Gut.

[4]  D. Tuveson,et al.  Stromal biology and therapy in pancreatic cancer: ready for clinical translation? , 2018, Gut.

[5]  Judy M. Anderson,et al.  Aberrant Expression of Mucin Core Proteins and O-Linked Glycans Associated with Progression of Pancreatic Cancer , 2013, Clinical Cancer Research.

[6]  D. Diamond,et al.  The pancreatic cancer microenvironment: A true double agent , 2017, Journal of surgical oncology.

[7]  V. Schweitzer PHOTOFRIN‐mediated photodynamic therapy for treatment of early stage oral cavity and laryngeal malignancies * , 2001, Lasers in surgery and medicine.

[8]  Jae Hoon Lee,et al.  The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study , 2017, Oncotarget.

[9]  J. Li,et al.  Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP‐TEAD complex , 2017, Cancer science.

[10]  Stephen G. Bown,et al.  Photodynamic Therapy Using Verteporfin Photosensitization in the Pancreas and Surrounding Tissues in the Syrian Golden Hamster , 2007, Pancreatology.

[11]  M. Magliano,et al.  Deciphering the role of stroma in pancreatic cancer , 2013, Current opinion in gastroenterology.

[12]  M. Korbelik,et al.  Cellular levels of photosensitisers in tumours: the role of proximity to the blood supply. , 1994, British Journal of Cancer.

[13]  D. Tuveson,et al.  Stromal biology and therapy in pancreatic cancer: a changing paradigm , 2015, Gut.

[14]  H. Ueno,et al.  Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer , 2017, Pancreas.

[15]  M. Roberge,et al.  The Autophagy Inhibitor Verteporfin Moderately Enhances the Antitumor Activity of Gemcitabine in a Pancreatic Ductal Adenocarcinoma Model , 2013, Journal of Cancer.

[16]  H. Kijima,et al.  Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. , 2001, Oncology reports.

[17]  S. Hirohashi,et al.  Orthotopic Transplantation Models of Pancreatic Adenocarcinoma Derived From Cell Lines and Primary Tumors and Displaying Varying Metastatic Activity , 2004, Pancreas.

[18]  T J Dougherty,et al.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. , 1976, Cancer research.

[19]  D. Gouma,et al.  Incidence and characteristics of chronic and lymphoplasmacytic sclerosing pancreatitis in patients scheduled to undergo a pancreatoduodenectomy. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[20]  T. Okumura,et al.  Activation of p38 mitogen-activated protein kinase is necessary for gemcitabine-induced cytotoxicity in human pancreatic cancer cells. , 2005, Anticancer research.

[21]  D. Aust,et al.  Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. , 2012, The Journal of surgical research.

[22]  A. Abioye,et al.  Pancreatic carcinoma. , 2020, Journal of the National Medical Association.

[23]  A. Andrén-sandberg,et al.  Photodynamic Therapy for Pancreatic Cancer , 2007, Pancreas.

[24]  J Moan,et al.  Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. , 1985, Cancer Research.

[25]  Lin Jia,et al.  Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. , 2009, World journal of gastroenterology.

[26]  M. Löhr,et al.  A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform , 2003, Virchows Archiv.

[27]  Dustin P. Jones,et al.  ECM Composition and Rheology Regulate Growth, Motility, and Response to Photodynamic Therapy in 3D Models of Pancreatic Ductal Adenocarcinoma , 2016, Molecular Cancer Research.

[28]  Julia Schüler,et al.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.

[29]  R. Gebhardt,et al.  Glial fibrillary acidic protein as a marker of perisinusoidal stellate cells that can distinguish between the normal and myofibroblast‐like phenotypes , 1996, Biology of the cell.

[30]  F. Real,et al.  Comparative analysis of mutations in the p53 and K‐ras genes in pancreatic cancer , 1994, International journal of cancer.

[31]  H. Kalthoff,et al.  Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosis , 2004, International journal of cancer.

[32]  J. Celli Stromal interactions as regulators of tumor growth and therapeutic response: A potential target for photodynamic therapy? , 2012, Israel journal of chemistry.

[33]  N. Nishioka,et al.  EUS-guided photodynamic therapy of the pancreas: a pilot study. , 2004, Gastrointestinal endoscopy.

[34]  J. Houghton,et al.  Shared pathways: Death receptors and cytotoxic drugs in cancer therapy , 2009, Pathology Oncology Research.

[35]  F. Hetzel,et al.  Effect of Photofrin-mediated photocytotoxicity on a panel of human pancreatic cancer cells. , 2013, Photodiagnosis and photodynamic therapy.

[36]  Y. Hirokawa,et al.  ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR expression of pancreatic cancer BxPC-3 cells at the invasive front in vitro, and promotes tumor growth and invasion in vivo , 2016, Oncology letters.

[37]  T. Dougherty Photodynamic therapy. , 1993, Photochemistry and photobiology.

[38]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[39]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[40]  F. Real,et al.  Genetic profile of 22 pancreatic carcinoma cell lines , 2001, Virchows Archiv.

[41]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[42]  K. T. Moesta,et al.  Evaluating the role of photodynamic therapy in the management of pancreatic cancer , 1995, Lasers in surgery and medicine.

[43]  T. Hasan,et al.  Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer , 2014, British Journal of Cancer.

[44]  B. Pogue,et al.  CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. , 2014, Physics in medicine and biology.

[45]  S. Batra,et al.  Mucins in pancreatic cancer and its microenvironment , 2013, Nature Reviews Gastroenterology &Hepatology.

[46]  E. Giovannetti,et al.  Unraveling the complexity of autophagy: Potential therapeutic applications in Pancreatic Ductal Adenocarcinoma. , 2015, Seminars in cancer biology.

[47]  Eric Wickstrom,et al.  Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction , 2003, BMC biotechnology.

[48]  T. Keck,et al.  The Role of Fibroblasts in Pancreatic Cancer: Extracellular Matrix Versus Paracrine Factors , 2017, Translational oncology.

[49]  M. Barrett,et al.  Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities. , 1998, Gastroenterology.

[50]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[51]  Brian W. Pogue,et al.  Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery. , 2018, Cancer research.

[52]  T. Hasan,et al.  Verteporfin‐based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines , 2011, Lasers in Surgery and Medicine.

[53]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[54]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[55]  R. Saxton,et al.  Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. , 2000, The Journal of surgical research.

[56]  S. Perkins,et al.  Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. , 2018, Gastrointestinal endoscopy.

[57]  S. Pereira,et al.  Photodynamic therapy for pancreatic carcinoma: experimental and clinical studies. , 2004, Photodiagnosis and photodynamic therapy.

[58]  P. Mukherjee,et al.  MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes , 2013, Oncogenesis.

[59]  Kenneth K Wang,et al.  Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines , 2012, Lasers in surgery and medicine.

[60]  G. Mills,et al.  Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. , 2016, American journal of cancer research.

[61]  A. Stojadinovic,et al.  An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. , 2003, Journal of the American College of Surgeons.

[62]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  T. Baron,et al.  Photodynamic therapy of intraductal papillary mucinous neoplasm , 2012, Endoscopy.

[64]  Tayyaba Hasan,et al.  Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. , 2003, Cancer research.

[65]  A. Maitra,et al.  The role of stromal cancer-associated fibroblasts in pancreatic cancer , 2017, Journal of Hematology & Oncology.

[66]  Evgueni Parilov,et al.  Interstitial Photodynamic Therapy—A Focused Review , 2017, Cancers.

[67]  Lian-Xin Liu,et al.  Use of photodynamic therapy in malignant lesions of stomach, bile duct, pancreas, colon and rectum. , 2007, Hepato-gastroenterology.

[68]  C. Sibata,et al.  Photosensitizers in clinical PDT. , 2004, Photodiagnosis and photodynamic therapy.

[69]  R. Bold,et al.  Gemcitabine-Induced Programmed Cell Death (Apoptosis) of Human Pancreatic Carcinoma Is Determined by Bcl-2 Content , 1999, Annals of Surgical Oncology.

[70]  G. Eibl,et al.  Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival , 2018, Signal Transduction and Targeted Therapy.